中产女性不买单，又一暴利行业崩塌

Core Viewpoint - The cosmetic medical industry in China, once seen as highly profitable, is now facing significant challenges due to increased competition and changing consumer attitudes, leading to a collective sense of anxiety among companies in the sector [4][6]. Group 1: Industry Overview - The cosmetic medical sector has experienced structural adjustments over the past four years, with many leading companies, including "medical beauty Maotai" Aimeike, facing declining performance and stock prices [4][6]. - Aimeike's dynamic price-to-earnings ratio has plummeted from over 300 times in 2021 to around 30 times, with its market capitalization dropping by approximately 120 billion yuan from its peak [4][6]. Group 2: Competitive Landscape - Aimeike is attempting to diversify its business by entering the "hair medical" field and launching new products, but the real market focus is on the competition for the exclusive agency rights of the "AestheFill" product [6][11]. - The ongoing dispute between Aimeike and Jiangsu Wuzhong over the exclusive rights to AestheFill highlights the intense competition and desperation within the industry as companies seek new growth opportunities [8][11]. Group 3: Financial Performance - Aimeike's revenue for the first quarter of the year was 663 million yuan, a year-on-year decrease of 17.9%, marking the first decline in nearly five years [26][29]. - The company's half-year report showed a revenue of 1.299 billion yuan, down 21.59% year-on-year, and a net profit of 789 million yuan, down 29.57% [27][29]. Group 4: Market Dynamics - The medical beauty market is experiencing a downturn, with 63% of institutions reporting revenue declines in the first half of 2025, and only 14% achieving growth [29][34]. - The competition has intensified, with price wars becoming common as companies struggle to maintain market share, leading to a significant slowdown in revenue growth for established players like Aimeike [32][34].